Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neuroone Medical Technologies (NMTC) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Neuroone Medical Technologies (NMTC) over the last 14 years, with Q4 2025 value amounting to -$1.4 million.

  • Neuroone Medical Technologies' Profit After Tax fell 18053.95% to -$1.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$6.8 million, marking a year-over-year increase of 499.87%. This contributed to the annual value of -$3.6 million for FY2025, which is 7073.11% up from last year.
  • Neuroone Medical Technologies' Profit After Tax amounted to -$1.4 million in Q4 2025, which was down 18053.95% from -$1.6 million recorded in Q3 2025.
  • Neuroone Medical Technologies' 5-year Profit After Tax high stood at $1.8 million for Q4 2024, and its period low was -$3.5 million during Q1 2023.
  • For the 5-year period, Neuroone Medical Technologies' Profit After Tax averaged around -$2.4 million, with its median value being -$2.8 million (2022).
  • Per our database at Business Quant, Neuroone Medical Technologies' Profit After Tax soared by 15337.45% in 2024 and then crashed by 18053.95% in 2025.
  • Over the past 5 years, Neuroone Medical Technologies' Profit After Tax (Quarter) stood at -$2.8 million in 2021, then soared by 38.28% to -$1.7 million in 2022, then plummeted by 93.04% to -$3.3 million in 2023, then skyrocketed by 153.37% to $1.8 million in 2024, then plummeted by 180.54% to -$1.4 million in 2025.
  • Its Profit After Tax was -$1.4 million in Q4 2025, compared to -$1.6 million in Q3 2025 and -$1.5 million in Q2 2025.